News | July 26, 2023
Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
